Chemistry:Mosliciguat

Mosliciguat
Clinical data
Other names	BAY 1237592
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (5S)-5-[2-(4-Carboxyphenyl)ethyl-[2-[2-[[2-chloro-4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]ethyl]amino]-5,6,7,8-tetrahydroquinoline-2-carboxylic acid;
CAS Number	2231749-54-3;
PubChem CID	154572869;
ChemSpider	115009506;
UNII	FL039XI4KF;
Chemical and physical data
Formula	C41H36ClF3N2O5
Molar mass	729.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@@H](C2=C(C1)N=C(C=C2)C(=O)O)N(CCC3=CC=C(C=C3)C(=O)O)CCC4=CC=CC=C4OCC5=C(C=C(C=C5)C6=CC=C(C=C6)C(F)(F)F)Cl;
	InChI InChI=1S/C41H36ClF3N2O5/c42-34-24-30(27-14-16-32(17-15-27)41(43,44)45)12-13-31(34)25-52-38-7-2-1-4-28(38)21-23-47(22-20-26-8-10-29(11-9-26)39(48)49)37-6-3-5-35-33(37)18-19-36(46-35)40(50)51/h1-2,4,7-19,24,37H,3,5-6,20-23,25H2,(H,48,49)(H,50,51)/t37-/m0/s1; Key:HFCWZVGKWGOBKV-QNGWXLTQSA-N;

Short description: Chemical compound

Mosliciguat (BAY 1237592) is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension.^[1]^[2]^[3]^[4]

References

↑ El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002. PMID 36921672.
↑ Friebe, Andreas; Kraehling, Jan R.; Russwurm, Michael; Sandner, Peter; Schmidtko, Achim (August 2023). "The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report". Naunyn-Schmiedeberg's Archives of Pharmacology 396 (8): 1669–1686. doi:10.1007/s00210-023-02484-8. PMID 37079081.
↑ Auth, Roger; Klinger, James R. (26 October 2023). "Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension". Expert Opinion on Investigational Drugs 32 (11): 1025–1042. doi:10.1080/13543784.2023.2274439. PMID 37881882.
↑ Becker-Pelster, Eva M.; Hahn, Michael G.; Delbeck, Martina; Dietz, Lisa; Hüser, Jörg; Kopf, Johannes; Kraemer, Thomas; Marquardt, Tobias et al. (1 October 2022). "Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC". Respiratory Research 23 (1). doi:10.1186/s12931-022-02189-1. PMID 36183104.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Mosliciguat. Read more

[1] El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002. PMID 36921672.

[2] Friebe, Andreas; Kraehling, Jan R.; Russwurm, Michael; Sandner, Peter; Schmidtko, Achim (August 2023). "The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report". Naunyn-Schmiedeberg's Archives of Pharmacology 396 (8): 1669–1686. doi:10.1007/s00210-023-02484-8. PMID 37079081.

[3] Auth, Roger; Klinger, James R. (26 October 2023). "Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension". Expert Opinion on Investigational Drugs 32 (11): 1025–1042. doi:10.1080/13543784.2023.2274439. PMID 37881882.

[4] Becker-Pelster, Eva M.; Hahn, Michael G.; Delbeck, Martina; Dietz, Lisa; Hüser, Jörg; Kopf, Johannes; Kraemer, Thomas; Marquardt, Tobias et al. (1 October 2022). "Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC". Respiratory Research 23 (1). doi:10.1186/s12931-022-02189-1. PMID 36183104.

[1]

[2]

[3]

[4]

Anonymous

Search

Chemistry:Mosliciguat

Namespaces

More

Page actions

References

Navigation

Navigation

Help

Translate

Wiki tools

Wiki tools

Anonymous

Search

Chemistry:Mosliciguat

References

Navigation

Wiki tools

Page tools

Other projects

Categories